Nervous System Symptoms Associated With COVID 19 : NS-COV
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Covid19
- Sponsor
- University Hospital, Toulouse
- Enrollment
- 99
- Locations
- 1
- Primary Endpoint
- percentage of patients in the Neuro + and Neuro- groups
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
This study aim to prospectively evaluate the neuropsychiatric symptoms of patients infected with the SARS-CoV-2 virus by a standardized neuropsychiatric examination : the global CASE scale (Clinical Assessment Scale in Autoimmune Encephalitis), and the prevalence of disturbances of consciousness, focal neurological deficit, cognitive impairment, headache, anosmia, sleep disturbances, impaired autonomic nervous system and peritraumatic stress.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Being hospitalized at the Toulouse University Hospital for a COVID-19 infection proven by a probable PCR or COVID-type examination on the chest scan
- •Have given oral consent for the collection of clinical neurological data
- •Be in a clinical state compatible with a 30-minute neurological examination
- •Be French-speaking
- •Be affiliated to a Social Security scheme
Exclusion Criteria
- •Refusal of the neurological examination
- •History of neurological pathology at a severe stage
- •Pregnant or breastfeeding woman
- •Persons with tutors or curators
Outcomes
Primary Outcomes
percentage of patients in the Neuro + and Neuro- groups
Time Frame: Baseline T0 : inclusion visit
The percentage is deducted from the score on a global scale by the Clinical Assessment Scale in Autoimmune Between 0 and 1, patients will be classified in the Neuro group, if this score is greater than or equal to 2, patients will be classified in the Neuro + group.